Barnaby Carr
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Barnaby Carr has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
Abdelrahman Farahat
Maidstone General Hospital, Maidstone, UK
1 shared publicationD. Alistair H. Laidlaw
Vitreoretinal Service, Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom
1 shared publicationHasan Ahmed
Peterborough City Hospital, Peterborough, UK
1 shared publicationHavena Harahn
Maidstone General Hospital, Maidstone, UK
1 shared publication- Imran Karim Janmohamed
Ophthalmology Department, Maidstone Hospital
1 shared publication - Luke Membrey
Maidstone General Hospital, Maidstone, UK.
1 shared publication
Latest Publications
- 14 April 2026
- Published by Springer Nature in Eye
- Vol. 40 (9) , 1351-1357
Early real-world outcomes of aflibercept 8 mg in previously treated neovascular age-related macular degeneration
Real-world evidence of aflibercept 8 mg in treatment-experienced patients remains limited. This study evaluated early outcomes of switching treatment-refractory patients with neovascular age-related macular degeneration (nAMD) to aflibercept 8 mg. This retrospective cohort study analysed previously-treated patients who switched to aflibercept 8 mg between January and June 2025. Best-corrected visual acuity (BCVA), central macular thickness (CMT), pigment epithelial detachment (PED) height, macular fluid status and treatment intervals were evaluated at baseline, 3 months, 6 months and final visit. 58 patients (66 eyes) were included. Patients received a mean 24.98 ± 18.04 anti-VEGF injections per eye over 49.41 ± 35.74 months pre-switch. Mean 5.15 ± 1.51 aflibercept 8 mg injections were administered per eye over a mean follow-up period of 25.86 ± 8.34 weeks. Median treatment intervals increased significantly from baseline to final visit (4 to 6 weeks, p < 0.001). 23 eyes (34.8%) achieved ≥8-week intervals by final follow-up. Median BCVA remained stable (70 ETDRS letters, interquartile range [IQR] 62-76 baseline and final follow-up, p = 0.571), as did median CMT (230.5 μm (IQR 189.5-281.2) at baseline to 226.5 μm (IQR 195-257) at final follow-up, p = 0.494). Median PED height showed a significant reduction (175 μm (IQR 106-287) at baseline to 173 μm (IQR 105-251) at final follow-up, p = 0.045). Complete macular fluid resolution occurred in 23.9% of eyes with baseline fluid at the final visit. No serious ocular adverse events occurred in this cohort. Aflibercept 8 mg demonstrated modest interval extension with stable functional and anatomical outcomes in heavily pre-treated nAMD patients. Long-term studies are needed to establish durability.
- 14 April 2026
- Published by Springer Nature in Eye
- Vol. 40 (9) , 1351-1357
Early real-world outcomes of aflibercept 8 mg in previously treated neovascular age-related macular degeneration
Real-world evidence of aflibercept 8 mg in treatment-experienced patients remains limited. This study evaluated early outcomes of switching treatment-refractory patients with neovascular age-related macular degeneration (nAMD) to aflibercept 8 mg. This retrospective cohort study analysed previously-treated patients who switched to aflibercept 8 mg between January and June 2025. Best-corrected visual acuity (BCVA), central macular thickness (CMT), pigment epithelial detachment (PED) height, macular fluid status and treatment intervals were evaluated at baseline, 3 months, 6 months and final visit. 58 patients (66 eyes) were included. Patients received a mean 24.98 ± 18.04 anti-VEGF injections per eye over 49.41 ± 35.74 months pre-switch. Mean 5.15 ± 1.51 aflibercept 8 mg injections were administered per eye over a mean follow-up period of 25.86 ± 8.34 weeks. Median treatment intervals increased significantly from baseline to final visit (4 to 6 weeks, p < 0.001). 23 eyes (34.8%) achieved ≥8-week intervals by final follow-up. Median BCVA remained stable (70 ETDRS letters, interquartile range [IQR] 62-76 baseline and final follow-up, p = 0.571), as did median CMT (230.5 μm (IQR 189.5-281.2) at baseline to 226.5 μm (IQR 195-257) at final follow-up, p = 0.494). Median PED height showed a significant reduction (175 μm (IQR 106-287) at baseline to 173 μm (IQR 105-251) at final follow-up, p = 0.045). Complete macular fluid resolution occurred in 23.9% of eyes with baseline fluid at the final visit. No serious ocular adverse events occurred in this cohort. Aflibercept 8 mg demonstrated modest interval extension with stable functional and anatomical outcomes in heavily pre-treated nAMD patients. Long-term studies are needed to establish durability.